Literature DB >> 8608796

ucb L059, a novel anticonvulsant, reduces bicuculline-induced hyperexcitability in rat hippocampal CA3 in vivo.

D G Margineanu1, E Wülfert.   

Abstract

Local diffusion of bicuculline from a bicuculline-containing recording micropipette increased the orthodromic field population spike (PS2), elicited upon commissural stimulation in the hippocampal CA3 region of anaesthetized rats. This increase in PS2 was consistently reduced by 5.4 mg/kg of the novel anticonvulsant drug ucb L059 ((S)-alpha-ethyl-2-oxo-pyrrolidine acetamide), when injected i.v. 10 min prior to lowering in place the bicuculline-containing micropipette. ucb L059 had no effect on PS2 in the absence of bicuculline. Paired-pulse stimulation produced marked inhibition of the second PS2 at low interstimulus interval, an effect which was significantly reduced by bicuculline. Although ucb L059 reduced the effect of bicuculline on both PS2S elicited by paired stimulations, the drug did not alter the reduction by bicuculline of paired-pulse inhibition at low interstimulus interval. These results suggest that ucb L059 prevents increases in CA3 neuronal excitability by bicuculline through a non gamma-aminobutyric acid-ergic mechanism.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8608796     DOI: 10.1016/0014-2999(95)00597-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

1.  New treatment options in status epilepticus: a critical review on intravenous levetiracetam.

Authors:  Eugen Trinka; Judith Dobesberger
Journal:  Ther Adv Neurol Disord       Date:  2009-03       Impact factor: 6.570

2.  Is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisited.

Authors:  Rainer Surges; Kirill E Volynski; Matthew C Walker
Journal:  Ther Adv Neurol Disord       Date:  2008-07       Impact factor: 6.570

3.  A comparison of the efficacy of carbamazepine and the novel anti-epileptic drug levetiracetam in the tetanus toxin model of focal complex partial epilepsy.

Authors:  H C Doheny; M A Whittington; J G R Jefferys; P N Patsalos
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

4.  A microdialysis study of the novel antiepileptic drug levetiracetam: extracellular pharmacokinetics and effect on taurine in rat brain.

Authors:  X Tong; P N Patsalos
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

Review 5.  Levetiracetam. A review of its adjunctive use in the management of partial onset seizures.

Authors:  M Dooley; G L Plosker
Journal:  Drugs       Date:  2000-10       Impact factor: 9.546

6.  Levetiracetam inhibits Na+-dependent Cl-/HCO3- exchange of adult hippocampal CA3 neurons from guinea-pigs.

Authors:  Tobias Leniger; Jan Thöne; Udo Bonnet; Andreas Hufnagel; Dieter Bingmann; Martin Wiemann
Journal:  Br J Pharmacol       Date:  2004-07-12       Impact factor: 8.739

7.  Levetiracetam.

Authors:  M Haria; J A Balfour
Journal:  CNS Drugs       Date:  1997-02       Impact factor: 5.749

8.  In the rat maximal dentate activation model of partial complex epilepsy, the anticonvulsant activity of levetiracetam is modulated by nitric oxide-active drugs.

Authors:  Pierangelo Sardo; Stefania D'Agostino; Valerio Rizzo; Fabio Carletti; Gioacchino Lonobile; Giuseppe Ferraro
Journal:  J Neural Transm (Vienna)       Date:  2009-05-12       Impact factor: 3.575

9.  Levetiracetam attenuates hippocampal expression of synaptic plasticity-related immediate early and late response genes in amygdala-kindled rats.

Authors:  Kenneth V Christensen; Henrik Leffers; William P Watson; Connie Sánchez; Pekka Kallunki; Jan Egebjerg
Journal:  BMC Neurosci       Date:  2010-01-27       Impact factor: 3.288

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.